Divi's Laboratories Limited — Others, 05-12-2024: News Verification

Divi's Laboratories has clarified that recent media reports regarding a US court ruling affecting Novartis's patent on a leading heart drug do not materially impact the company. As a Contract Manufacturing Organization, Divi's has existing supply agreements with various customers, ensuring stability in operations. The management emphasized their commitment to timely disclosures under applicable regulations, indicating no anticipated changes that would affect shareholder interests. This clarification may provide a positive outlook for investors, alleviating concerns over potential risks associated with external pharmaceutical litigations.